BR112019000709A2 - sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário - Google Patents
sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuárioInfo
- Publication number
- BR112019000709A2 BR112019000709A2 BR112019000709A BR112019000709A BR112019000709A2 BR 112019000709 A2 BR112019000709 A2 BR 112019000709A2 BR 112019000709 A BR112019000709 A BR 112019000709A BR 112019000709 A BR112019000709 A BR 112019000709A BR 112019000709 A2 BR112019000709 A2 BR 112019000709A2
- Authority
- BR
- Brazil
- Prior art keywords
- user
- antibiotic
- assessing
- condition
- operable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Data Mining & Analysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Nursing (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
Abstract
sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário as realizações de um método e de um sistema para farmacogenômicos microbianos podem incluir: um sistema de manipulação de amostra operável para coletar recipientes incluindo amostras biológicas a partir de um conjunto de usuários, o sistema de manipulação incluindo um sistema de sequenciamento operável para determinar as sequências de microrganismos a partir de amostras biológicas; um sistema de caracterização de microbioma operável para: determinar dados de farmacogenômicos de microbioma baseados nas sequências de microrganismos, coletar dados suplementares associados com a condição associada aos antibióticos para o conjunto de usuários e transformar os dados suplementares e as características extraídas dos dados de farmacogenômicos de microbioma em um modelo de caracterização associado com a condição associada aos antibióticos; e um sistema de tratamento operável para promover um tratamento ao usuário para a condição associada aos antibióticos com base na caracterização do material biológico do usuário com o modelo de caracterização em relação à condição associada aos antibióticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361943P | 2016-07-13 | 2016-07-13 | |
US15/606,743 US10803991B2 (en) | 2014-10-21 | 2017-05-26 | Method and system for microbiome-derived diagnostics and therapeutics |
PCT/US2017/042015 WO2018013865A1 (en) | 2016-07-13 | 2017-07-13 | Method and system for microbial pharmacogenomics |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112019000709A2 true BR112019000709A2 (pt) | 2019-05-14 |
BR112019000709A8 BR112019000709A8 (pt) | 2023-03-21 |
Family
ID=60953350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019000709A BR112019000709A8 (pt) | 2016-07-13 | 2017-07-13 | Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3484348A4 (pt) |
JP (2) | JP2019521706A (pt) |
KR (1) | KR102397683B1 (pt) |
CN (1) | CN109475305B (pt) |
AU (1) | AU2017295861A1 (pt) |
BR (1) | BR112019000709A8 (pt) |
CA (1) | CA3030792A1 (pt) |
CO (1) | CO2019001319A2 (pt) |
EA (1) | EA201990294A1 (pt) |
SG (1) | SG11201900253TA (pt) |
WO (1) | WO2018013865A1 (pt) |
ZA (1) | ZA201900473B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3720969A4 (en) * | 2017-12-04 | 2021-08-11 | Cybele Microbiome, Inc. | PROCEDURES AND COMPOSITIONS FOR IDENTIFICATION AND MODULATION OF BIOCHEMICAL MICROBIOMA PATHS TO CHANGE THE PHENOTYPE |
KR20200132954A (ko) * | 2018-03-16 | 2020-11-25 | 소마젠 인크 | 생물정보학 접근법에 근거한 진단 및 요법을 포함하는 대사-관련 컨디션의 특성화를 위한 방법 및 시스템 |
CN112292697A (zh) * | 2018-04-13 | 2021-01-29 | 弗里诺姆控股股份有限公司 | 用于生物样品的多分析物测定的机器学习实施方式 |
WO2019234246A1 (en) * | 2018-06-07 | 2019-12-12 | 4D Pharma Plc | Method for stratifying ibs patients |
KR102346398B1 (ko) | 2020-09-01 | 2022-01-03 | 주식회사 에이아이바이오틱스 | 장내 미생물을 분석하여 평가 하는 시스템 및 평가 방법 |
US20220367050A1 (en) * | 2021-05-12 | 2022-11-17 | Zoe Limited | Predicting gut microbiome diversity |
KR20240099759A (ko) | 2022-12-22 | 2024-07-01 | 주식회사 오디엔 | 약물치료 관리 시스템 및 그 동작방법 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996017951A2 (en) * | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
CN1798548B (zh) * | 2003-06-02 | 2010-05-05 | 诺华疫苗和诊断公司 | 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物 |
AU2005337803B2 (en) * | 2005-10-29 | 2013-04-18 | Bayer Intellectual Property Gmbh | Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof |
CN104031984A (zh) * | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
EP2362907A4 (en) * | 2008-11-04 | 2012-08-08 | Blood Cell Storage Inc | NUCLEAR ACID EXTRACTION ON DOVED GLASS SURFACES |
JP2013517889A (ja) * | 2010-01-29 | 2013-05-20 | ユーバイオメッド インク. | マイクロニードル及びマイクロニードル装置 |
DK2547361T3 (da) * | 2010-03-17 | 2020-11-23 | Socpra Sciences Et Genie Sec | Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf |
CN101833613A (zh) * | 2010-06-04 | 2010-09-15 | 中国科学院青岛生物能源与过程研究所 | 一种口腔微生物群落数据库及其应用 |
US20130121968A1 (en) * | 2011-10-03 | 2013-05-16 | Atossa Genetics, Inc. | Methods of combining metagenome and the metatranscriptome in multiplex profiles |
WO2013176774A1 (en) * | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
US20140143188A1 (en) * | 2012-11-16 | 2014-05-22 | Genformatic, Llc | Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy |
EP3584308A3 (en) * | 2013-02-04 | 2020-03-04 | Seres Therapeutics, Inc. | Compositions and methods |
CN105339023A (zh) * | 2013-03-15 | 2016-02-17 | 普迈针药物公司 | 用于经皮递送化合物的设备、系统和方法 |
US9466024B2 (en) * | 2013-03-15 | 2016-10-11 | Northrop Grumman Systems Corporation | Learning health systems and methods |
US20150019189A1 (en) * | 2013-07-01 | 2015-01-15 | Counterpoint Health Solutions, Inc. | Systems biology approach to therapy |
WO2015013214A2 (en) * | 2013-07-21 | 2015-01-29 | Whole Biome, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
WO2015066625A1 (en) * | 2013-11-01 | 2015-05-07 | Washington University | Methods to establish and restore normal gut microbiota function of subject in need thereof |
WO2015112352A2 (en) * | 2014-01-25 | 2015-07-30 | uBiome, Inc. | Method and system for microbiome analysis |
WO2016057679A1 (en) * | 2014-10-09 | 2016-04-14 | LuminaCare Solutions Inc. | Personalized antibiotic dosing platform |
WO2016065075A1 (en) * | 2014-10-21 | 2016-04-28 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
CA2969825A1 (en) * | 2014-12-05 | 2016-06-09 | University Of Saskatchewan | Methods and reagents for detecting neisseria gonorrhoeae and its antimicrobial resistance determinants |
CN105648060B (zh) * | 2016-01-29 | 2020-01-31 | 江汉大学 | 一种非诊断目的的人体病原微生物耐药性基因的检测方法 |
-
2017
- 2017-07-13 EP EP17828501.1A patent/EP3484348A4/en active Pending
- 2017-07-13 SG SG11201900253TA patent/SG11201900253TA/en unknown
- 2017-07-13 CN CN201780043788.6A patent/CN109475305B/zh active Active
- 2017-07-13 WO PCT/US2017/042015 patent/WO2018013865A1/en unknown
- 2017-07-13 JP JP2019522621A patent/JP2019521706A/ja not_active Withdrawn
- 2017-07-13 AU AU2017295861A patent/AU2017295861A1/en not_active Abandoned
- 2017-07-13 BR BR112019000709A patent/BR112019000709A8/pt not_active Application Discontinuation
- 2017-07-13 EA EA201990294A patent/EA201990294A1/ru unknown
- 2017-07-13 KR KR1020197004007A patent/KR102397683B1/ko active IP Right Grant
- 2017-07-13 CA CA3030792A patent/CA3030792A1/en active Pending
-
2019
- 2019-01-23 ZA ZA2019/00473A patent/ZA201900473B/en unknown
- 2019-02-13 CO CONC2019/0001319A patent/CO2019001319A2/es unknown
-
2022
- 2022-03-31 JP JP2022058908A patent/JP2022079646A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3484348A4 (en) | 2021-11-24 |
JP2019521706A (ja) | 2019-08-08 |
CN109475305A (zh) | 2019-03-15 |
ZA201900473B (en) | 2019-09-25 |
KR20190033561A (ko) | 2019-03-29 |
WO2018013865A1 (en) | 2018-01-18 |
EA201990294A1 (ru) | 2019-08-30 |
KR102397683B1 (ko) | 2022-05-13 |
EP3484348A1 (en) | 2019-05-22 |
JP2022079646A (ja) | 2022-05-26 |
CO2019001319A2 (es) | 2019-02-19 |
SG11201900253TA (en) | 2019-02-27 |
CA3030792A1 (en) | 2018-01-18 |
BR112019000709A8 (pt) | 2023-03-21 |
CN109475305B (zh) | 2022-01-25 |
AU2017295861A1 (en) | 2019-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019000709A2 (pt) | sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário | |
WO2017172644A3 (en) | Bacteria identification and antibiotic susceptibility profiling device | |
BR112019005025A2 (pt) | sistema e método para caracterizar um painel | |
WO2015112352A3 (en) | Method and system for microbiome analysis | |
MY192493A (en) | Urinalysis device and dry reagent for quantitative urinalysis | |
BR112016018981A2 (pt) | métodos e sistemas para rápida detecção de microrganismos usando bacteriófago recombinante | |
WO2019079624A3 (en) | Msi from liquid biopsies | |
Mort et al. | Ex vivo live imaging of melanoblast migration in embryonic mouse skin | |
Unno et al. | Toxoplasma gondii tachyzoite-infected peripheral blood mononuclear cells are enriched in mouse lungs and liver | |
EP2977467A3 (en) | Method, use of marker, and determination device for obtaining information on plural types of cancers | |
Turner et al. | Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? | |
BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
EP3009842A3 (en) | Method for supporting diagnosis of risk of colorectal cancer recurrence, program and computer system | |
Ruf et al. | Spatial distribution of Mycobacterium ulcerans in Buruli ulcer lesions: implications for laboratory diagnosis | |
Martinez-Fernandez et al. | Sample processing methods impacts on rumen microbiome | |
EP2176432A4 (en) | METHOD OF DETECTING DISEASE MARKERS | |
Dogan et al. | Physoxia influences global and gene-specific methylation in pluripotent stem cells | |
Kuroda et al. | In vitro detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human induced pluripotent stem cells | |
WO2016051177A3 (en) | Methods and kits | |
EP3878979A3 (en) | Molecular detection of enterovirus and parechovirus | |
PL410454A1 (pl) | Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy | |
PL403996A1 (pl) | Sposób jednoczesnej detekcji bakterii i grzybów w preparacie biologicznym metodą PCR, startery oraz zestaw do detekcji bakterii i grzybów | |
CN105255880A (zh) | 一种海胆物种特异性检测引物及应用 | |
McCracken et al. | Development of 26 novel microsatellite makers for the round whitefish (Prosopium cylindraceum) and successful polymorphic cross-specific amplification of seven previously developed salmonid markers | |
Cajander | Dynamics of Human Leukocyte Antigen-D Related expression in bacteremic sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61B 5/00 , A61K 35/74 Ipc: A61B 5/00 (2006.01), C12Q 1/689 (2018.01) |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |